Patents by Inventor Thomas Ichim

Thomas Ichim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF LIVER FAILURE BY EX VIVO REPROGRAMMED IMMUNE CELLS
    Publication number: 20220202861
    Abstract: Disclosed are methods, means and compositions of matter useful for treatment of liver failure using ex vivo reprogrammed immune cells. In one embodiment, cells of the recipient (autologous) are cocultured with a regenerative cell population alone or in the presence of one or more adjuvants. Said adjuvants enhance transfer of regenerative activity from said mesenchymal stem cells to said immune cells. In one embodiment said ex vivo reprogrammed immune cells are capable of inducing death or inactivation of hepatic stellate cells. In other embodiments, said immune cells provide antifibrotic activity to induce suppression of liver cirrhosis. In other embodiments, said immune cells provide for growth factors to enhance hepatic regeneration.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 30, 2022
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Amit Patel, Timothy Warbington
  • TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLS
    Publication number: 20220202860
    Abstract: Disclosed are methods, means and compositions of matter useful for treatment of heart failure, and/or post infarct pathological remodeling using ex vivo reprogrammed immune cells. In one embodiment, cells of the recipient (autologous) are cocultured with a regenerative cell population alone or in the presence of one or more adjuvants. Said adjuvants enhance transfer of regenerative activity from said mesenchymal stem cells to said immune cells. In one embodiment said ex vivo reprogrammed immune cells are capable of inducing death or inactivation of cardiac fibrotic cells. In other embodiments, said immune cells provide antifibrotic activity to induce suppression of cardiac fibrosis. In other embodiments, said immune cells provide for growth factors to enhance cardiac regeneration.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 30, 2022
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Amit Patel
  • Nutraceutical Reduction Prevention and/or Reversion of Multiple Sclerosis
    Publication number: 20220193170
    Abstract: Disclosed are compositions of matter, protocols, and treatment means for preventing and/or reversing multiple sclerosis in a mammal. In one embodiment administration of compositions containing pterostilbene, and/or Nigella sativa, and/or sulforaphane, and/or epigallocatechin-3-gallate (EGCG) are provided.
    Type: Application
    Filed: October 19, 2021
    Publication date: June 23, 2022
    Inventors: Thomas Ichim, J. Christopher Mizer, Timothy G. Dixon, Famela Ramos, Kalina O'Connor
  • IMMUNOTHERAPY FOR OPIOID ADDICTION
    Publication number: 20220193127
    Abstract: Disclosed are means, methods and compositions of matter useful for reduction of brain inflammation and prevention of opioid addiction and/or tolerance. In one embodiment the invention provides utilization of platelet rich plasma (PRP), alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiments PRP is admixed with oxytocin and administered intranasally in a patient at risk of opioid addiction. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil, and/or pterostilbene and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 23, 2022
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas Ichim, Timothy G. Dixon, Famela Ramos, Wais Kaihani, James Veltmeyer, Kalina O'Connor
  • INDUCTION OF INFECTIOUS TOLERANCE BY EX VIVO REPROGRAMMED IMMUNE CELLS
    Publication number: 20220175835
    Abstract: Disclosed are means, methods and compositions of matter useful for inhibiting, in an antigen-specific manner, immunity towards an autoantigen or alloantigen. In one embodiment of the invention, regenerative cells are cultured ex vivo together with immune cells from a mammal suffering from an autoimmune condition. Autoantigens or alloantigens are added in the culture of regenerative cells and cells from an autoimmune disease suffering individual in a manner so that said regenerative cells can endow onto said immune cells of said patient suffering from autoimmunity a state of antigen specific infectious tolerance. In one embodiment, said infectious tolerance involves T regulatory cells inducing conversion of dendritic cells to tolerogeneic dendritic cells, and furthermore in other embodiments administration of tolerogenic dendritic cells induces T regulatory cells.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 9, 2022
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Amit Patel
  • TREATMENT OF MAJOR DEPRESSIVE DISORDER AND SUICIDAL IDEATIONS THROUGH STIMULATION OF HIPPOCAMPAL NEUROGENESIS UTILIZING PLANT-BASED APPROACHES
    Publication number: 20220175701
    Abstract: Disclosed are means and methods of treating major depressive disorder and/or other disorders that predispose to suicide by administration of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor cells. In one embodiment said nutraceuticals are comprised of green tea extract, and/or Nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiment's nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.
    Type: Application
    Filed: December 8, 2021
    Publication date: June 9, 2022
    Applicant: THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
    Inventors: Thomas Ichim, Timothy G. Dixon, James Veltmeyer, Kalina O'Connor
  • Stimulation of NK Cell Activity by QuadraMune Alone and together with Metformin
    Publication number: 20220160809
    Abstract: Disclosed are means, compounds, and compositions of matter useful for stimulation of natural killer cell activity. On one embodiment a composition termed QuadraMune™ comprised of In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of metformin, pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients with COVID-19.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 26, 2022
    Inventors: Thomas Ichim, Timothy G. Dixon, Famela Ramos, Wais Kaihani
  • FIBROBLAST REGENERATIVE CELLS
    Publication number: 20220110979
    Abstract: Disclosed are compositions, systems and methods comprising a regenerative fibroblast cell, population or subsets thereof possessing regenerative activity useful for treatment of various degenerative diseases. In one embodiment, the disclosure provides fibroblasts with enhanced proliferative potential based on enrichment for CD105 and/or CD117 markers. In one embodiment, fibroblasts possessing CD105 and/or CD117 markers are further enriched for the property of rhodamine 123 efflux.
    Type: Application
    Filed: January 13, 2020
    Publication date: April 14, 2022
    Inventors: Pete O'Heeron, Thomas Ichim
  • Therapeutic Cancer Immune Modulation by Treatment with mTOR Inhibitors
    Publication number: 20220079930
    Abstract: Disclosed are means, methods, and protocols useful for treatment of cancer through the previously unknown immune stimulatory effects of mTOR inhibitors and derivatives/analogues thereof. In one embodiment the invention provides the use of mTOR inhibitors to overcome cancer mediated immune exhaustion/anergy. While in conventional situations it is widely known that mTOR inhibitors possesses immune suppressive functions, hence their use in prevention of allograft rejection, our findings suggest that these inhibitors may overcome cancer induced immune suppression and/or exhaustion of immune cell proliferative activities. In some embodiments mTOR inhibitors are utilized together with checkpoint inhibitors. In other embodiments, mTOR inhibitors are administered after lymphodepletion to augment effects of homeostatically expanded lymphocytes.
    Type: Application
    Filed: April 5, 2021
    Publication date: March 17, 2022
    Inventors: Thomas Ichim, Santosh Kesari
  • AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS
    Publication number: 20220040087
    Abstract: Disclosed are means, methods and compositions of matter useful for amplification of adaptive immune responses towards neoplastic tissue. In one embodiment, immunization of a patient is performed by a means comprising of administering either an exogenous vaccine or stimulation of immunogenicity of the tumor so as to cause release of antigens/increased exposure of antigens, thus resulting in an “endogenous” vaccine. Subsequent to vaccination a patient is treated by an immunopheresis procedure, in order to allow for removal of “blocking factors” produced by the tumor or produced by cells programmed by tumors to produce said blocking factors.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 10, 2022
    Applicant: IMMUNICOM, INC.
    Inventors: Thomas ICHIM, Amir JAFRI, Steven F. JOSEPHS
  • AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS
    Publication number: 20220040088
    Abstract: Disclosed are means, methods and compositions of matter useful for amplification of adaptive immune responses towards neoplastic tissue. In one embodiment, immunization of a patient is performed by a means comprising of administering either an exogenous vaccine or stimulation of immunogenicity of the tumor so as to cause release of antigens/increased exposure of antigens, thus resulting in an “endogenous” vaccine. Subsequent to vaccination a patient is treated by an immunopheresis procedure, in order to allow for removal of “blocking factors” produced by the tumor or produced by cells programmed by tumors to produce said blocking factors.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 10, 2022
    Applicant: IMMUNICOM, INC.
    Inventors: Thomas ICHIM, Amir JAFRI, Steven F. JOSEPHS
  • Small molecule modulators of NR2F6 activity
    Patent number: 11241427
    Abstract: Disclosed are compounds useful for alteration of NR2F6 activity. In some embodiments of the invention compounds disclosed are utilized for stimulation of NR2F6 activity, alone, or in combination with PKC activation. In other embodiments, the invention teaches use of compounds for inhibition of NR2F6 activation. Stimulation of NR2F6 within the context of the invention is useful, intra alia, for induction of immune inhibition, or stimulation of cellular proliferation without significant induction of differentiation. Inhibition of NR2F6 is desired in situations where the practitioner of the invention seeks to augment immune response, or induce cellular differentiation. In another embodiment, inhibition of NR2F6 expression is desired in situations where inhibition of cancer or cancer stem cells is needed.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 8, 2022
    Assignee: KCL Therapeutics, Inc.
    Inventors: David Koos, Thomas Ichim
  • THERAPEUTIC USES OF GENE EDITED FIBROBLASTS
    Publication number: 20220025332
    Abstract: The present disclosure is directed to methods and compositions of engineered fibroblast cells with one or more types of modifications such that the cell has a reduced immune response either alone, in association with other immune cells, or both. In some embodiments, one or more targets are modified on the surface of the cell. In specific embodiments, engineered cells to be used in cellular transplantation therapy are modified to have reduced immunogenicity.
    Type: Application
    Filed: December 16, 2019
    Publication date: January 27, 2022
    Inventors: Pete O'HEERON, Thomas ICHIM
  • TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
    Publication number: 20220023349
    Abstract: Embodiments of the disclosure concern methods and compositions related to treatment of cachexia or inflammation related thereto. In specific embodiments, cachexia or inflammation related thereto is to treated or prevented by the administration of fibroblasts. In specific embodiments, the fibroblasts are amniotic-derived fibroblasts.
    Type: Application
    Filed: November 4, 2019
    Publication date: January 27, 2022
    Inventors: Pete O'Heeron, Thomas Ichim
  • TREATMENT OF CEREBRAL HYPOXIA INCLUDING STROKE, CHRONIC TRAUMATIC ENCEPHALOPATHY, AND TRAUMATIC BRAIN INJURY
    Publication number: 20220023350
    Abstract: Disclosed are methods, compositions of matter, and means of treatment or prophylaxis using fibroblasts possessing regenerative properties for the treatment of brain injuries including stroke, transient ischemic injuries, chronic traumatic encephalopathy, traumatic brain injury, and tauopathies. Embodiments of the disclosure administer fibroblasts with regenerative properties either systemically, locally, or a combination of the two prior to, concurrent with, or subsequent to a brain injury. In some embodiments of the disclosure fibroblasts or products thereof, are administered intranasally, intrathecally, and/or intravenously.
    Type: Application
    Filed: November 4, 2019
    Publication date: January 27, 2022
    Inventors: Pete O'Heeron, Thomas Ichim
  • METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT
    Publication number: 20220000934
    Abstract: Embodiments of the disclosure pertain to the treatment of diabetes through replacement of insulin producing cells. In specific embodiments, the disclosure encompasses the use of cellular adjuvants to enhance survival, engraftment and tolerogenesis of insulin-producing cells. In certain cases the disclosure concerns the manipulation of a hepatic microenvironment to promote immunological tolerance at an enhanced level to allow for integration of allogeneic insulin-producing cells. Particular embodiments utilize fibroblasts to enhance immunological tolerance for insulin-producing cells upon engraftment.
    Type: Application
    Filed: November 4, 2019
    Publication date: January 6, 2022
    Inventors: Pete O'Heeron, Thomas Ichim
  • ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL
    Publication number: 20210403866
    Abstract: Cancer associated inflammation has been reported to act as an immune suppressive mechanism through augmentation of myeloid suppressor cells, as well as downregulation of T cell receptor (TCR) signaling through the cleavage of the CD3 zeta chain. The teachings herein show the effects of concurrent anti-inflammatory treatment of dendritic cells (DC) using cannabidiol (CBD) together with inhibition of an immunological checkpoint, that is, silencing of NR2F6. Mixed lymphocyte cultures are used to increased potency of dendritic cells to stimulate allogeneic T cell proliferative and cytokine responses by the combination of NR2F6 gene silencing together with CBD. CBD alone appeared to inhibit DC maturation and allogestimulatory activity. These data support the utilization of small molecule inhibitors of NR2F6 together with CBD as combination therapies for immune modulation.
    Type: Application
    Filed: September 29, 2020
    Publication date: December 30, 2021
    Applicant: Regen Biopharma, Inc.
    Inventors: Thomas Ichim, David Koos
  • INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF
    Publication number: 20210393700
    Abstract: The present disclosure is directed to systems, methods, and compositions for functional interaction of fibroblasts with one or more types of immune cells such that the interaction results in modification to the fibroblasts, the one or more types of immune cells, or both. In some embodiments, one or more certain agents are also utilized during the interaction or in lieu of one of the types of cells. In specific embodiments, cells to be used in cellular transplantation therapy are modified to have reduced immunogenicity.
    Type: Application
    Filed: November 29, 2018
    Publication date: December 23, 2021
    Inventors: Pete O'Heeron, Thomas Ichim
  • MEANS AND METHODS OF PREVENTING OR REVERSING AGING
    Publication number: 20210395691
    Abstract: The present disclosure provides means of regenerating/restoring aged and/or damaged tissue or treating a medical condition by providing an extracorporeal circuit containing cells, including fibroblasts or dedifferentiated fibroblasts. that are in contact with plasma but not blood cells extracorporeally in a manner allowing for exchange of factors between a subject and an extracorporeally residing mass of cells. The disclosure provides means of titrating factors produced by the extracorporeal regenerative cell mass, thus allowing for a regenerative effect.
    Type: Application
    Filed: November 8, 2019
    Publication date: December 23, 2021
    Inventors: Pete O'Heeron, Thomas Ichim
  • REGENERATIVE ABSCOPAL EFFECTS
    Publication number: 20210393701
    Abstract: Embodiments of the disclosure encompass methods and compositions using fibroblasts for stimulating regeneration in a first tissue site in an individual, comprising the step of administering at least one regenerative composition to a second tissue site, wherein the second tissue site comprises the same tissue type as the first tissue site in the individual. The first and second sites are at different locations in the individual, in particular embodiments. Particular embodiments comprise administering one or more compositions to an individual at a different anatomical site than the site that is in need, such as a joint.
    Type: Application
    Filed: November 8, 2019
    Publication date: December 23, 2021
    Inventors: Pete O'Heeron, Thomas Ichim